



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**  
**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

### Faculty disclosures report

The 2022 COMy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COSTEM participants. In doing so, the 2022 COMy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

#### Educational Content Development

The 2022 COMy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

#### Presenters

The 2022 COMy Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2022 COMy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2022 COMy Congress of CME based on the CME providers of the Congress.

All 2022 COMy Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2022 COMy Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

#### 2022 COMy Financial Disclosure Codes

Type of affiliation / financial interest	Code
Receipt of grants/research supports:	S
Receipt of consultation / advisory board / employment fees:	C
Lecture and/or honoraria fees:	L
Stock shareholder or equity owner:	O
Patents/royalties:	P
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**

**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

#### **Disclosure Information**

Financial interest disclosures from program members and others in a position for control content:

#### **Kenneth Anderson, USA**

C Astra Zeneca, Janssen, Mona, Pfizer, Precision Biosciences, Starton, Window  
O C4 Therapeutics, Oncopep, Raqia, NextRNA

#### **Hervé Avet-Loiseau, France**

*Nothing to declare*

#### **Nizar Bahlis, Canada**

S Celgene, Pfizer  
C Amgen, AbbVie, Celgene/BMS, Genentech, GSK, Janssen, Karyopharm, Pfizer, Sanofi, Takeda

#### **Meral Beksac, Turkey**

C Amgen, Janssen, Oncopeptides, Sanofi, Takeda  
L Amgen, Janssen, Sanofi, Takeda

#### **Joan Bladé, Spain**

L Amgen, Celgene/BMS, Janssen, Karyopharm, Oncopeptides, Sanofi, Takeda

#### **Michele Cavo, Italy**

C,L AbbVie, Amgen, Celgene/BMS, Janssen, GSK, Sanofi, Takeda

#### **Ajai Chari, USA**

S Amgen, Array Biopharma, Celgene, GSK, Janssen, Millenium/Takeda, Novartis  
C Amgen, BMS, Celgene, Janssen, Karyopharm, Millenium/Takeda  
L BMS, Janssen, Takeda

#### **Jill Corre, France**

*Nothing to declare*

#### **Luciano Costa, USA**

S Amgen, BMS, Janssen  
C Adaptive Bio, Amgen, BMS, Janssen, Sanofi  
L Amgen, Sanofi

#### **Michel Delforge, Belgium**

S,L Amgen, BMS, Janssen, Sanofi, Takeda

#### **Meletios Dimpoulos, Greece**

L Amgen, Beigene, BMS, Janssen, Takeda

#### **Hermann Einsele, Germany**

S Amgen, Celgene/BMS, GSK, Janssen, Sanofi  
C,L Amgen, Celgene/BMS, GSK, Janssen, Novartis, Sanofi

#### **Theirry Facon, France**

*Nothing to declare*



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**

**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

**Francesca Gay, Italy**

- C AbbVie, Amgen, Celgene/BMS, Janssen, Oncopeptides, Pfizer Roche, Sanofi, Takeda
- L AbbVie, Amgen, Celgene/BMS, Janssen, Sanofi, Takeda

**Irene Ghobrial, USA**

- C AbbVie, Adaptive Bio, Amgen, Binding Site, BMS, Celgene, Cellectar, GSK, Janssen, Menarini Silicon Biosystems, Novartis, Oncopeptides, Pfizer, Sanofi, Takeda
- L Amgen, BMS, Celgene, Janssen, Takeda

**Jean-Luc Harousseau, France**

- C GKS, Oncopeptides

**Graham Jackson, UK**

- S Amgen, Celgene/BMS, Onyx, Takeda
- C Amgen, Celgene/BMS, GSK, Janssen, Oncopeptides, Sanofi, Seagan, Takeda
- L Amgen, Janssen, Oncopeptides, Sanofi

**Martin Kaiser, UK**

- S Celgene/BMS, Janssen
- C AbbVie, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm, Pfizer, Seattle Biotech, Takeda
- L Celgene/BMS, Janssen, Takeda

**Sigurdur Kristinsson, Iceland**

*Nothing to declare*

**Shaji Kumar, USA**

- S AbbVie, Amgen, Astra Zeneca, BMS, Carsgen, Janssen, Molecular Templates, Novartis, Roche-Genentech, Takeda, Tenebio
- C AbbVie, Amgen, Antengene, Astra Zeneca, Beigene, bluebirdbio, BMS, Epizyme, GLH Pharma, Janssen, Monterosa Therapeutics, Oncopeptides, Roche-Genentech, Secura Biotherapeutics, Takeda, Trillium

**Alessandro Larocca, Italy**

- C,L Amgen, BMS, GSK, Janssen-Cilag, Oncopeptides, Sanofi, Takeda

**Xavier Leleu, France**

- L AbbVie, Amgen, BMS, GSK, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda

**Sagar Lonial, USA**

- S BMS, Janssen, Novartis, Takeda
- C AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Novartis, Takeda
- O TG Therapeutics

**Heinz Ludwig, Austria**

- S Amgen, Sanofi
- C Janssen, Oncopeptides
- L Amgen, Janssen, Sanofi, Takeda

**Salomon Manier, France**

*Nothing to declare*



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**

**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

**María-Victoria Mateos, Spain**

- C AbbVie, Adaptive Bio, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm, Pfizer, Oncoceptides, Regeneron, Sanofi, Sea-Gen, Takeda
- L AbbVie, Adaptive Bio, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm, Oncoceptides, Sanofi, Takeda

**Giampaolo Merlino, Italy**

- C Attralus, Janssen, Novo, Pfizer

**Mohamad Mohty, France**

- S Janssen, Sanofi
- C Amgen, BMS, Janssen, Pfizer, Sanofi, Takeda

**Philippe Moreau, France**

- C AbbVie, Amgen, Celgene, Janssen, Roche, Sanofi

**Gareth Morgan, USA**

- C BMS, Celgene, Genentech, Janssen, Karyopharm, Roche, Sanofi

**Nikhil Munshi, USA**

- C AbbVie, Amgen, BMS, Janssen, Oncoceptides, Novartis, Pfizer, Takeda
- O,P Oncoceptides

**Arnon Nagler, Israel**

*Nothing to declare*

**Paola Neri, Canada**

- C BMS, Janssen, Sanofi

**Enric Ocio, Spain**

- C Amgen, Celgene/BMS, GSK, Janssen, Karyopharm, Pfizer, Oncoceptides, Sanofi, Takeda
- L Amgen, Celgene/BMS, GSK, Janssen, Oncoceptides, Sanofi, Takeda

**Bruno Paiva, Spain**

- S Celgene/BMS, Roche, Sanofi
- C Celgene/BMS, GSK, Janssen, Roche, Sanofi, Takeda
- L Adaptive Bio, Becton Dickinson, Celgene/BMS, Creative Biolabs, GSK, Janssen, Roche, Sanofi, Takeda

**Torben Plesner, Denmark**

- C AbbVie, Celgene, CSL Behring, Genentech, Janssen, Oncoceptides, Takeda
  - L Janssen
  - O Novo Nordic
- Other, research: AbbVie, Celgene, Genentech, Genmab, Janssen, Roche, Takeda*

**Marc Raab, Germany**

- S AbbVie, Amgen, GSK
- C Amgen, BMS, Janssen, Novartis, Sanofi, Takeda

**Noopor Raje, USA**

*Nothing to declare*



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**

**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

**Vincent Rajkumar, USA**

*Nothing to declare*

**Paul Richardson, USA**

S Celgene/BMS, Karyopharm, Oncopeptides, Takeda

S Astra Zeneca, Celgene/BMS, GSK, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Secura Bio, Takeda

**Jesus San Miguel, Spain**

C AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, MSD, Novartis, Regeneron, Roche, Sanofi, Secura Bio, Takeda

**Pieter Sonneveld, The Netherlands**

S Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda

C Amgen, BMS, Celgene, Janssen, Karyopharm, SkylineDx, Takeda

**Andrew Spencer, Australia**

*Nothing to declare*

**Evangelos Terpos, Greece**

S GSK, Janssen, Sanofi, Takeda

C GSK, Sanofi, Takeda

L BMS, Genesis, GSK, Pfizer, Sanofi, Sandoz, Takeda

**Cyrille Touzeau, France**

S AbbVie, GSK, Sanofi

C AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Sanofi, Takeda

**Steve Treon, USA**

C Janssen

L Beigene, Janssen

**Suzanne Trudel, Canada**

S Amgen, BMS, Genetech, GSK, Janssen, Pfizer, Roche

C BMS, GSK, Roche

L BMS, GSK, Janssen, Roche, Sanofi

**Saad Usmani, USA**

S Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacoclics, Sanofi, Seattle Genetics, SkylineDx, Takeda

C Amgen, BMS, Celgene, EdoPharma, Gilead, Genentech, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, TeneoBio

L Amgen, BMS, Janssen, Sanofi

**Niels van de Donk, The Netherlands**

S Amgen, BMS, Celgene, Cellectis, Janssen, Novartis

C Adpative Bio, Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Roche, Servier, Takeda



The World Congress in  
**CONTROVERSIES IN MULTIPLE MYELOMA**

**8<sup>th</sup> COMy Congress – Paris, France & Online – May 12-14, 2022**

**Katia Weisel**, Germany

S Amgen, Celgene/BMS, GSK, Janssen, Sanofi

L AbbVie, Adaptive Bio, Amgen, Celgene/BMS, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Takeda

**Kwee Yong**, UK

*Nothing to declare*

**Elena Zamagni**, Italy

L Amgen, BMS, GSK, Janssen, Sanofi, Takeda

**Sonja Zweegman**, The Netherlands

S Janssen, Takeda

C Amgen, Celgene/BMS, Janssen, Oncopeptides, Sanofi, Takeda